Dorsmanin A is primarily investigated for its potential antitumor and anticancer properties. It exhibits strong inhibitory effects against certain types of cancer cells by inducing apoptosis and disrupting cell cycle progression. Research suggests it may be effective against drug-resistant cancer lines, making it a candidate for development in chemotherapy adjuvants. Its mechanism involves targeting specific signaling pathways involved in tumor growth and metastasis. Due to its natural origin and selective cytotoxicity, it is also studied for use in targeted cancer therapies with reduced side effects. Further applications are being explored in combination therapies to enhance the efficacy of existing anticancer drugs.